H5NI流感疫苗国际合作研究取得进展 作者:李磊来源:中国科学报2012-7-5 14:59:34 日前,泰国成为全球首批开展无针、喷鼻剂配方H5N1流感疫苗测试的国家。该减毒流感疫苗的第一阶段临床试验,是泰国与包括美国卫生部高级生物医学研究和发展局(BARDA)在内的全球卫生机构开展国际合作所取得的结果。BARDA官员Robin Robinson表示,流感疫苗仍然是全球公共卫生应急准备的关键组分。通过强化发展中国家研发、制造和测试自产流感疫苗的能力,将有助于改善全球的流感应对准备工作。 Robinson表示,这一成果喻示旨在加速全世界流感疫苗生产本地化的国际合作取得了一个里程碑似的成绩。世界卫生组织(WHO)代表泰国政府,与总部设在澳大利亚墨尔本的Biodiem公司商谈该疫苗的许可权。该疫苗起初由俄罗斯实验医学研究所(IEM)研发,随后IEM 将疫苗的许可权转给Biodiem公司。通过向WHO提供资助,BARDA为泰国和其他发展中国家提供了资金和技术的支持。(生物谷Bioon.com)
Thailand begins trial on H5N1 nasal
spray vaccine Via Vaccine News Daily: June 08, 2012Thailand begins trial on
avian influenza nasal spray vaccine. Thailand
recently became one of the first countries to test a needle-free nasal spray
vaccine against H5N1 avian influenza. The vaccine is the result of an
international collaboration between health agencies from around the world, including
the U.S. Health and Human Services’ Biomedical Advanced Research and
Development Authority, according to PHE.org. The phase I clinical trials mark
the first step in testing the live attenuated influenza vaccine for safety and
efficacy in humans. “Influenza vaccines remain a critical component of public
health preparedness worldwide,” BARDA Director Dr. Robin Robinson said, PHE.org
reports. “By enhancing the capacity of developing countries to develop, manufacture
and test their own influenza vaccines, we are improving pandemic preparedness
globally.” Robinson called the clinical trial a milestone in the development of
international efforts aimed at accelerating the development of local vaccines
throughout the world.
No comments:
Post a Comment